Headaches

Ariane K. Kawata, Ray Hsieh, Randall Bender, Shannon Shaffer, Dennis A. Revicki, Martha Bayliss, Dawn C. Buse, Pooja Desai, Sandhya Sapra, Brian Ortmeier, Asha Hareendran September 3, 2017

Objective

The objective of this study was to evaluate the measurement properties of the Migraine Physical Function Impact Diary (MPFID), a novel patient-reported outcome (PRO) measure for assessing the impact of migraine on physical functioning.

Methods

In a prospective, observational study, adults with episodic migraine (EM) or chronic migraine (CM) used an eDiary to complete the MPFID (assessing daily impacts of migraine on physical function) and a headache diary (capturing migraine days, migraine pain intensity, and migraine interference) each day, and other PRO instruments related to migraine.

Read More...
Hsiangkuo Yuan, Stephen D. Silberstein September 3, 2017

Background

Histamine is an ancient “tissue amine” preceding multicellular organisms. In the central nervous system (CNS), its fibers originate solely from the tuberomammillary nucleus and travel throughout the brain. It is mainly responsible for wakefulness, energy homeostasis, and memory consolidation. Recently, several studies suggest a potential role of histamine in migraine pathogenesis and management.

Read More...
Joshua M. Cohen, David W. Dodick, Ronghua Yang, Lawrence C. Newman, Thomas Li, Ernesto Aycardi, Marcelo E. Bigal September 3, 2017

Background

Fremanezumab (formerly TEV-48125) is a monoclonal antibody directed against calcitonin-gene-related peptide (CGRP), a validated target for migraine preventive therapy. In two previous phase 2 studies, fremanezumab administered once every 28 days for 12 weeks was found to be effective and safe as a preventive treatment for patients suffering from episodic migraine (EM) and chronic migraine (CM).

Read More...

Andoird App
Loading...